Heidi Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Australian AI clinical documentation platform. Used by Monash Health (1.6M patients). $96.6M raised ($65M Series B at $465M valuation). Founded 2019, Melbourne.
About
Heidi Health was founded in 2019 in Melbourne, Australia by Dr. Thomas Kelly and Ryan Wright to eliminate the administrative burden of clinical documentation for healthcare providers. Clinicians spend 30–50% of working hours on documentation — typing notes, generating referral letters, completing forms — time that could otherwise go to patient care. Heidi built an ambient AI documentation platform that listens to patient consultations, transcribes in real time, and automatically generates structured clinical notes and referral letters tailored to each clinician's specialty.\n\nThe platform integrates with major EHR systems to push completed notes directly into patient charts, eliminating copy-paste friction. The AI engine supports general practice, specialist medicine, allied health, and nursing, and learns each clinician's personal documentation style over time to reduce editing effort. Heidi is deployed at Monash Health in Victoria, one of Australia's largest public health networks serving 1.6 million patients, as a flagship enterprise reference deployment.\n\nHeidi Health has raised $96.6 million in total funding, including a $65 million Series B at a $465 million valuation. The company is one of the fastest-growing clinical documentation AI platforms in Australia and is expanding internationally. As health systems globally address clinician burnout driven by documentation load, ambient AI documentation is emerging as a high-ROI technology investment, positioning Heidi Health alongside US-based competitors including Nuance DAX and Suki.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.